Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
/ 85 items
#LLY↓
Lilly and Ascidian Sign $1.9B Deal to Bring RNA Gene Editing to Genetic Kidney Diseases
Eli Lilly teams with Ascidian to use RNA editing to treat rare kidney diseases without changing DNA.
Eli Lilly Spends Nearly $4 Billion to Enter the Vaccine Market
Eli Lilly is buying 3 vaccine firms for up to $4B to expand beyond diabetes and obesity into infectious disease vaccines.
Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss in Phase 3 Trial, Analysts Stay Bullish
Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.
Lilly Buys Engage Bio for $202M to Unlock Safer, Repeatable DNA Therapies
Eli Lilly buys Engage Bio for up to $202M to boost safer gene therapy using non-viral DNA delivery technology.
Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.